Literature DB >> 34078641

Function-related Indicators and Outcomes of Screening Mammography in Older Women: Evidence from the Breast Cancer Surveillance Consortium Cohort.

Dongyu Zhang1,2, Linn Abraham3, Joshua Demb4, Diana L Miglioretti3,5, Shailesh Advani6, Brian L Sprague7, Louise M Henderson8, Tracy Onega9, Karen J Wernli3, Louise C Walter10, Karla Kerlikowske10,11, John T Schousboe12,13, Ellen S O'Meara3, Dejana Braithwaite.   

Abstract

BACKGROUND: Previous reports suggested risk of death and breast cancer varied by comorbidity and age in older women undergoing mammography. However, impacts of functional limitations remain unclear.
METHODS: We used data from 238,849 women in the Breast Cancer Surveillance Consortium-Medicare linked database (1999-2015) who had screening mammogram at ages 66-94 years. We estimated risk of breast cancer, breast cancer death, and non-breast cancer death by function-related indicator (FRI) which incorporated 16 claims-based items and was categorized as an ordinal variable (0, 1, and 2+). Fine and Gray proportional sub-distribution hazards models were applied with breast cancer and death treated as competing events. Risk estimates by FRI scores were adjusted by age and NCI comorbidity index separately and stratified by these factors.
RESULTS: Overall, 9,252 women were diagnosed with breast cancer, 406 died of breast cancer, and 41,640 died from non-breast cancer causes. The 10-year age-adjusted invasive breast cancer risk slightly decreased with FRI score [FRI = 0: 4.0%, 95% confidence interval (CI) = 3.8-4.1; FRI = 1: 3.9%, 95% CI = 3.7-4.2; FRI ≥ 2: 3.5%, 95% CI = 3.1-3.9). Risk of non-breast cancer death increased with FRI score (FRI = 0: 18.8%, 95% CI = 18.5-19.1; FRI = 1: 24.4%, 95% CI = 23.9-25.0; FRI ≥ 2: 39.8%, 95% CI = 38.8-40.9]. Risk of breast cancer death was low with minimal differences across FRI scores. NCI comorbidity index-adjusted models and stratified analyses yielded similar patterns.
CONCLUSIONS: Risk of non-breast cancer death substantially increases with FRI score, whereas risk of breast cancer death is low regardless of functional status. IMPACT: Older women with functional limitations should be informed that they may not benefit from screening mammography. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34078641      PMCID: PMC8563300          DOI: 10.1158/1055-9965.EPI-21-0152

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  36 in total

1.  Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness.

Authors:  K Kerlikowske; P Salzmann; K A Phillips; J A Cauley; S R Cummings
Journal:  JAMA       Date:  1999-12-08       Impact factor: 56.272

2.  Breast cancer in older women: what factors affect the treatment?

Authors:  Alessandro Sanguinetti; Andrea Polistena; Roberta Lucchini; Massimo Monacelli; Stefano Avenia; Claudia Conti; Ivan Barillaro; Fabio Rondelli; Walter Bugiantella; Nicola Avenia
Journal:  Int J Surg       Date:  2014-08-23       Impact factor: 6.071

3.  Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database.

Authors:  R Ballard-Barbash; S H Taplin; B C Yankaskas; V L Ernster; R D Rosenberg; P A Carney; W E Barlow; B M Geller; K Kerlikowske; B K Edwards; C F Lynch; N Urban; C A Chrvala; C R Key; S P Poplack; J K Worden; L G Kessler
Journal:  AJR Am J Roentgenol       Date:  1997-10       Impact factor: 3.959

4.  The impact of functional status on life expectancy in older persons.

Authors:  Emmett Keeler; Jack M Guralnik; Haijun Tian; Robert B Wallace; David B Reuben
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-04-02       Impact factor: 6.053

5.  Predictive value of functional limitation for disease severity in patients with mild chronic heart failure.

Authors:  Yuji Kono; Sumio Yamada; Kotaro Iwatsu; Sato Nitobe; Yuko Tanaka; Yuko Shimizu; Norihiro Shinoda; Takahiro Okumura; Akihiro Hirashiki; Toyoaki Murohara
Journal:  J Cardiol       Date:  2012-08-13       Impact factor: 3.159

6.  Development of a comorbidity index using physician claims data.

Authors:  C N Klabunde; A L Potosky; J M Legler; J L Warren
Journal:  J Clin Epidemiol       Date:  2000-12       Impact factor: 6.437

Review 7.  Screening mammography in older women: a review.

Authors:  Louise C Walter; Mara A Schonberg
Journal:  JAMA       Date:  2014-04-02       Impact factor: 56.272

8.  Mammography use in relation to comorbidities and functional limitations among older breast cancer survivors.

Authors:  Dongyu Zhang; Shailesh Advani; Zhikai Zhu; Le Dang; Louise C Walter; Dejana Braithwaite
Journal:  J Cancer Surviv       Date:  2020-07-28       Impact factor: 4.442

9.  Breast cancer surgery in elderly patients: postoperative complications and survival.

Authors:  Nicola Rocco; Corrado Rispoli; Gennaro Pagano; Giuseppe Rengo; Rita Compagna; Michele Danzi; Antonello Accurso; Bruno Amato
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

10.  Multimorbidity, functional limitations, and outcomes: Interactions in a population-based cohort of older adults.

Authors:  Alanna M Chamberlain; Lila J Finney Rutten; Debra J Jacobson; Chun Fan; Patrick M Wilson; Walter A Rocca; Véronique L Roger; Jennifer L St Sauver
Journal:  J Comorb       Date:  2019-09-09
View more
  2 in total

1.  Mammography adherence in relation to function-related indicators in older women.

Authors:  Dongyu Zhang; Linn Abraham; Brian L Sprague; Tracy Onega; Shailesh Advani; Joshua Demb; Diana L Miglioretti; Louise M Henderson; Karen J Wernli; Louise C Walter; Karla Kerlikowske; John T Schousboe; Elizabeth Chrischilles; Dejana Braithwaite; Ellen S O'Meara
Journal:  Prev Med       Date:  2021-11-09       Impact factor: 4.018

2.  "It's something I'll do until I die": A qualitative examination into why older women in the U.S. continue screening mammography.

Authors:  Laura E Brotzman; Rachel C Shelton; Jessica D Austin; Carmen B Rodriguez; Mariangela Agovino; Nathalie Moise; Parisa Tehranifar
Journal:  Cancer Med       Date:  2022-05-26       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.